Precision BioSciences, Inc. (DTIL): Price and Financial Metrics
DTIL Price/Volume Stats
| Current price | $0.38 | 52-week high | $1.70 |
| Prev. close | $0.39 | 52-week low | $0.38 |
| Day low | $0.38 | Volume | 633,700 |
| Day high | $0.41 | Avg. volume | 793,903 |
| 50-day MA | $0.51 | Dividend yield | N/A |
| 200-day MA | $0.83 | Market Cap | 43.77M |
DTIL Stock Price Chart Interactive Chart >
DTIL POWR Grades
- DTIL scores best on the Sentiment dimension, with a Sentiment rank ahead of 96.23% of US stocks.
- DTIL's strongest trending metric is Value; it's been moving up over the last 160 days.
- DTIL ranks lowest in Stability; there it ranks in the 12th percentile.
DTIL Stock Summary
- For DTIL, its debt to operating expenses ratio is greater than that reported by merely 9.64% of US equities we're observing.
- With a year-over-year growth in debt of -79.65%, PRECISION BIOSCIENCES INC's debt growth rate surpasses merely 2.41% of about US stocks.
- In terms of volatility of its share price, DTIL is more volatile than 87.24% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to PRECISION BIOSCIENCES INC are RXRX, EFTR, SLDP, SRPT, and ALGS.
- DTIL's SEC filings can be seen here. And to visit PRECISION BIOSCIENCES INC's official web site, go to www.precisionbiosciences.com.
DTIL Valuation Summary
- DTIL's EV/EBIT ratio is 1; this is 91.94% lower than that of the median Healthcare stock.
- Over the past 54 months, DTIL's EV/EBIT ratio has gone up 17.3.
Below are key valuation metrics over time for DTIL.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DTIL | 2023-09-18 | 1.0 | 1.4 | -0.5 | 1.0 |
| DTIL | 2023-09-15 | 1.0 | 1.4 | -0.5 | 1.0 |
| DTIL | 2023-09-14 | 1.0 | 1.4 | -0.5 | 1.0 |
| DTIL | 2023-09-13 | 1.1 | 1.5 | -0.6 | 0.9 |
| DTIL | 2023-09-12 | 1.1 | 1.5 | -0.6 | 0.9 |
| DTIL | 2023-09-11 | 1.1 | 1.5 | -0.6 | 0.9 |
DTIL's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DTIL has a Quality Grade of C, ranking ahead of 57.32% of graded US stocks.
- DTIL's asset turnover comes in at 0.5 -- ranking 82nd of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows DTIL's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.500 | 1 | -1.846 |
| 2021-03-31 | 0.176 | 1 | -3.839 |
| 2020-12-31 | 0.135 | 1 | -3.174 |
| 2020-09-30 | 0.109 | 1 | -3.116 |
| 2020-06-30 | 0.087 | 1 | -3.034 |
| 2020-03-31 | 0.097 | 1 | -2.717 |
DTIL Price Target
For more insight on analysts targets of DTIL, see our DTIL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $19.13 | Average Broker Recommendation | 1.45 (Moderate Buy) |
Precision BioSciences, Inc. (DTIL) Company Bio
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.
Latest DTIL News From Around the Web
Below are the latest news stories about PRECISION BIOSCIENCES INC that investors may wish to consider to help them evaluate DTIL as an investment opportunity.
This Precision BioSciences Insider Increased Their Holding By 38% Last YearViewing insider transactions for Precision BioSciences, Inc.'s ( NASDAQ:DTIL ) over the last year, we see that insiders... |
Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program DevelopmentsDURHAM, N.C., September 12, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that the Company plans to highlight its current development programs, pipeline updates, and underlying ARCUS platform technology during a virtual R&D Day to be held today at 9:00 AM ET. |
Precision BioSciences to Attend and Present at Upcoming September Investor ConferencesDURHAM, N.C., September 06, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that members of management will participate in the following investor conferences in the month of September: |
Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023DURHAM, N.C., August 31, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced that it will host its in vivo gene editing R&D Day on Tuesday, September 12, 2023 from 9:00-11:30 AM ET. |
Why Durham biotech's pivot means smaller, leaner companyPrecision BioSciences has sold its lead cell therapy asset as the company shifts focus exclusively to gene editing. |
DTIL Price Returns
| 1-mo | -25.49% |
| 3-mo | -33.32% |
| 6-mo | -50.48% |
| 1-year | -68.85% |
| 3-year | -93.56% |
| 5-year | N/A |
| YTD | -68.07% |
| 2022 | -83.92% |
| 2021 | -11.27% |
| 2020 | -39.96% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...